Ablexis delivers a transgenic mouse platform for the discovery of therapeutic antibodies.

Ablexis, LLC

Ablexis

Ablexis, LLC | 499 followers on LinkedIn. A superior, next generation transgenic platform. | Ablexis offers the AlivaMab® Mouse platform, a suite of transgenic mouse strains for human therapeutic antibody discovery. AlivaMab Mouse strains are uniquely designed to be better for human therapeutic antibody discovery and development, for applications across antibody drug discovery including highest quality IgGs, singe-domain VH, multispecifics, ADCs, CARs, TCRm, and other modalities.  The AlivaMab Mouse strains are well-documented for generating drug-like antibodies with broad combinatorial and somatic diversities, high affinities, specificity, and excellent developability properties.

Thanks, Ian Wilkinson, for adding to the conversation about the importance of human Ig lambda light chains. I wholeheartedly agree about lambda light chains being important for engaging certain epitopes, either altogether or with sufficient affinity to meet potency requirements. I have 20+ years of accumulated anecdotal evidence, first using XenoMouse(R) Mice and now using AlivaMab(R) Mice.

From the 2014 generation 1 of AlivaMab Mouse to the generation 6 versions now being launched, we recognized the importance of including a well-functioning human Ig lambda light chain locus to maximize probability of success in antibody drug discovery. Our partners have benefited from that foresight. Talk to us to learn about the benefits of other unique design features incorporated into the AlivaMab Mouse strains that make them the best platform choice for antibody drug discovery.

Last year's Innovation Day was inspiring and a lot of fun. Meet us in San Diego at Innovation Day 2024 - it will be even better!

Jane always does a fantastic job in leading discussions and moderating panels. This will be a "can't miss" session!

Join the team at AlivaMab Biologics and help discover the next great biologic drug to improve patients' outcomes!

Don't miss this roundtable! Jane will do a great job in leading a scintillating discussion and debate.

Ablexis and AlivaMab Biologics celebrate our ten years of innovations in antibody drug discovery, commencing in 2014 with launch of the 1st generation AlivaMab® Mouse strains and continuing onward with our launching of the 6th generation AlivaMab Mouse strains, used in synergy with the innovative high-throughput discovery and engineering platforms of AlivaMab Biologics. The patented AlivaMab Mouse technology remains a platform differentiated from other transgenic animals and in vitro display technologies, providing superior performance and efficiency in antibody discovery while risk-mitigating downstream development. Our most recent innovations include the AlivaMab Mouse-XKL strains, demonstrated to produce even greater combinatorial diversity in the IgG repertoire, and AlivaMab Mouse-SD, for the discovery of single-domain human VH antibodies. For common light chain antibody discovery, AlivaMab Biologics offers its unique platform that combines the best of in vivo, in vitro, and NGS-based discovery. To learn more about why AlivaMab Mouse and AlivaMab Biologics provide the best platforms for biologics drug discovery and engineering, contact us at info@alivamab.com or info@ablexis.com .

Thank you to the many people with whom we met at East Coast Antibody HubXChange! Lots of follow-ups!

Another AlivaMab antibody achieves an important clinical milestone!

Come meet with us next week in Woburn, MA at East Coast Antibody HubXChange. Jane will be presenting beautiful data about creating, interrogating, and capturing incredible antibody diversity for superior biologics drug discovery.

ABLE

COM:ABLEXIS

Ablexis

name

homepage url

country

linkedin url

crunchbase url

sector

industry

stage

raised capital

Description

peer of

Metrics